Researchers discover long-acting injectable medicine as potential route to COVID-19 therapy ANI | Updated: May 05, 2021 22:09 IST
Liverpool [UK], May 5 (ANI): Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.
In a paper published in the journal Nanoscale, researchers from the University s Centre of Excellence for Long-acting Therapeutics (CELT) demonstrate the nanoparticle formulation of niclosamide, a highly insoluble drug compound, as a scalable long-acting injectable antiviral candidate.
The team started repurposing and reformulating identified drug compounds with the potential for COVID-19 therapy candidates within weeks of the first lockdown. Niclosamide is just one of the drug compounds identified and has been shown to be highly effective against SARS-CoV-2 in a number of laboratory studies.
E-Mail
Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.
In a paper published in the journal
Nanoscale, researchers from the University s Centre of Excellence for Long-acting Therapeutics (CELT) demonstrate the nanoparticle formulation of niclosamide, a highly insoluble drug compound, as a scalable long-acting injectable antiviral candidate.
The team started repurposing and reformulating identified drug compounds with the potential for COVID-19 therapy candidates within weeks of the first lockdown. Niclosamide is just one of the drug compounds identified and has been shown to be highly effective against SARS-CoV-2 in a number of laboratory studies.
Repurposing an existing, cheap drug into long-acting injectable therapy to treat Covid-19
Apr 16 2021
Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.
Image Credit: University of Liverpool
In a paper published in the journal
Nanoscale, researchers from the University’s Centre of Excellence for Long-acting Therapeutics (CELT) demonstrate the nanoparticle formulation of niclosamide, a highly insoluble drug compound, as a scalable long-acting injectable antiviral candidate.
The team started repurposing and reformulating identified drug compounds with the potential for COVID-19 therapy candidates within weeks of the first lockdown. Niclosamide is just one of the drug compounds identified and has been shown to be highly effective against SARS-CoV-2 in a number of laboratory studies.
Jan 30 2021 Read 2446 Times
Asynt has supplied Polymer Mimetics with a range of synthetic chemistry equipment to exploit novel chemistries to produce a new generation of high-performance polymers.
Polymer Mimetics is a joint venture between the University of Liverpool, and Scott Bader Company Ltd building upon a new polymerisation process developed by Professor Steve Rannard from the University’s Department of Chemistry. The technology takes widely available chemical building blocks and, in a highly scalable process, transforms them into superior performance polymeric products with the potential to engineer in degradability.
Dr Paul Findlay, Chief Technology Offer at Polymer Mimetics, said: Since the 1950 s less than 10% of the billions of tons of plastic produced worldwide has been recycled - the rest has been sent to landfill or left in the natural environment. Using our new polymerisation technology, we can produce novel polymers to address some of the issues associated wit